Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Key Points

• Barclays cut its Ultragenyx price target from $35 to $32 but maintained an Overweight rating; the target implied about 100% upside from the prior close.
• Shares fell 7% to $15.97 during Thursday trading. Ultragenyx reported a quarterly loss of $1.16 per share and revenue of $173 million, both missing analyst expectations, although revenue grew 8.2% year over year.
• Analyst opinion was mixed, with MarketBeat reporting an average Hold rating and an average price target of $30.32.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its price target decreased by equities researchers at Barclays from $35.00 to $32.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an "overweight" rating on the biopharmaceutical company's stock. Barclays's target price suggests a potential upside of 100.43% from the company's previous close.

RARE has been the topic of several other research reports. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. JPMorgan Chase & Co. lowered Ultragenyx Pharmaceutical from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $80.00 to $36.00 in a research report on Thursday, September 3rd. Wells Fargo & Company boosted their price target on Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the company an "equal weight" rating in a report on Wednesday. Canaccord Genuity Group lowered their price target on Ultragenyx Pharmaceutical from $39.00 to $34.00 and set a "buy" rating for the company in a report on Wednesday. Finally, UBS Group initiated coverage on Ultragenyx Pharmaceutical in a research report on Thursday, October 15th. They set a "neutral" rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $30.32.

Ultragenyx Pharmaceutical Stock Down 7.0%

Shares of RARE traded down $1.19 during midday trading on Thursday, hitting $15.97. The company had a trading volume of 3,231,126 shares, compared to its average volume of 2,874,377. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -3.07 and a beta of 0.37. The company's 50 day moving average price is $16.45 and its 200 day moving average price is $22.78. Ultragenyx Pharmaceutical has a 52 week low of $12.73 and a 52 week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The firm had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. The business's revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.81) earnings per share. Equities analysts anticipate that Ultragenyx Pharmaceutical will post -4.30 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer owned 89,229 shares of the company's stock, valued at $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,510 shares of company stock worth $127,561 in the last quarter. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $355,746,000. Bank of America Corp DE acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $38,347,000. Jefferies Financial Group Inc. acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $31,040,000. Eagle Health Investments LP bought a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $18,522,000. Finally, Palo Alto Investors LP bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $19,916,968. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reported FDA approvals for GENGLYCOS and FAYUVI and agreed to sell two Priority Review Vouchers for a combined $413 million. It also reaffirmed its 2027 profitability outlook and expects R&D expenses in 2027 to be at least 50% below 2025 levels. Third-quarter results and guidance
• Neutral Sentiment: Analyst views were mixed: Canaccord maintained a Buy despite cutting its target to $34; TD Cowen raised its target to $19, and Morgan Stanley raised its target to $22 while retaining Equal Weight. Goldman Sachs and Wedbush lowered their targets to $17 and $22, respectively, with Neutral ratings. Analyst insights
• Negative Sentiment: Third-quarter revenue of $173 million missed analyst expectations of about $182.5 million, and the $1.16-per-share loss was wider than the roughly $1.10 loss expected. Revenue grew 8.2% year over year and the loss narrowed from a year earlier, but the shortfall may weigh on sentiment. Q3 earnings coverage
• Negative Sentiment: A critical investor assessment points to dependence on CRYSVITA, limited contributions from newer launches, and pipeline setbacks. It argues that the path toward profitability relies heavily on deep R&D cuts rather than strong revenue growth. Assessment of Ultragenyx’s outlook

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx's commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.